MiMedx Group, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
MiMedx develops and commercializes placental biologics for wound care, burn, and surgical applications. The company operates primarily in the United States, with a limited international presence. This unaudited Form 10-Q covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
The Regenerative Medicine business unit and knee osteoarthritis clinical trial program were disbanded in 2023; related results are presented as discontinued operations.
Financial Performance and Liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $84.7 million | $71.7 million | Up 18.2% |
| Gross profit | $71.7 million | $59.3 million | Up 21.0% |
| Gross margin | 84.7% | 82.7% | Up 200 basis points |
| Operating income | $13.2 million | $(0.3) million | Improved by $13.5 million |
| Net income from continuing operations | $9.1 million | $(1.9) million | Improved by $11.0 million |
| Net income | $9.3 million | $(5.0) million | Improved by $14.2 million |
| Diluted earnings per share | $0.06 | $(0.06) | Improved |
| Operating cash flow | $6.0 million | $(4.0) million | Improved by $10.0 million |
Continuing-operations operating cash flow was $6.8 million versus $0.6 million in the prior-year quarter. Total operating cash flow included $(0.8) million from discontinued operations. Cash used in investing activities was $6.0 million, including the $5.0 million initial payment for the TELA transaction and $1.1 million of equipment purchases. Cash used in financing activities was $33.5 million, principally reflecting debt refinancing and repayment activity, financing costs, and $2.2 million of shares withheld for employee tax obligations.
Cash and cash equivalents were $48.5 million at March 31, 2024, down from $82.0 million at December 31, 2023. Current assets were $138.9 million and current liabilities were $42.2 million, producing a reported current ratio of 3.3. Management stated that cash, operating cash flow, and available credit are expected to satisfy operational liquidity needs for the twelve months following the filing date.
Revenue and Margin Drivers
- Wound revenue increased 26.2% to $57.0 million, driven particularly by private-office sales.
- Surgical revenue increased 4.5% to $27.7 million, supported by AMNIOEFFECT and, to a lesser extent, AXIOFILL. The prior-year surgical comparison included approximately $1.0 million of discontinued dental product sales.
- Revenue by site of service increased in hospitals to $43.8 million, private offices to $30.3 million, and other sites to $10.6 million.
- Gross-margin expansion reflected favorable product mix and yield-improvement initiatives.
- SG&A increased 5.5% to $55.1 million, primarily due to higher commissions and a greater proportion of sales through agents.
- Research and development expense decreased 18.5% to $2.8 million, primarily due to lower headcount and activity timing.
- Investigation, restatement, and related expense declined 91.5% to $0.3 million as material obligations under a prior indemnification proceeding substantially ceased in 2023.
Debt and Capital Structure
On January 19, 2024, MiMedx entered into a Citizens senior secured credit agreement providing a $75.0 million revolving facility and a $20.0 million term loan, with a January 19, 2029 maturity date. Initial borrowings were $30.0 million under the revolver and $20.0 million under the term loan. The revolver drawing was repaid on February 27, 2024, leaving no revolver borrowings and $75.0 million of availability at March 31, 2024.
The refinancing repaid the prior $50.0 million Hayfin term loan and resulted in a $1.4 million loss on extinguishment of debt. The Citizens term loan carried a 7.9% interest rate at March 31, 2024. Reported debt consisted of $1.0 million of current maturities and $18.5 million of long-term debt, net of discounts and financing costs. The credit agreement includes maximum net-leverage and minimum fixed-charge-coverage covenants, as well as customary restrictive covenants.
Material Changes, Outlook, and Unusual Items
- Management characterized Q1 commercial performance as strong and highlighted 18.2% year-over-year sales growth, improved profitability, debt refinancing, product portfolio expansion, two new independent directors, and a new online ordering and account-management platform.
- On March 15, 2024, MiMedx acquired exclusive U.S. selling and marketing rights for a 510(k)-cleared collagen particulate xenograft product from TELA and entered into a supply agreement with Regenity. The transaction was recorded as an asset acquisition with $8.1 million of recognized assets, including $7.6 million of distribution rights and $0.5 million of inventory.
- The TELA/Regenity arrangements require future payments based on product sales of between $3.0 million and $7.0 million, acquisition of remaining inventory for approximately $0.4 million, and minimum annual product purchases through December 31, 2033. Failure to meet purchase minimums could result in non-exclusive distribution rights.
- On March 25, 2024, the FDA reaffirmed its position that AXIOFILL does not qualify as a Section 361 Human Cell, Tissue or Cellular or Tissue-based Product. MiMedx disagrees and filed suit against the FDA; the outcome and potential business impact remain uncertain.
- The company disclosed ongoing litigation, including the Welker RICO action and indemnification-related litigation involving former executives. No potential losses related to legal matters were accrued as of March 31, 2024, and the company cannot predict ultimate outcomes.
- Interest-rate exposure remains material because the term loan is based on one-month Term SOFR and is not hedged. Management estimates that a 100-basis-point change in SOFR would change annualized interest expense by approximately $0.2 million.
- No material changes were reported to the risk factors in the 2023 Form 10-K. The company provided no quantitative revenue or earnings guidance in the filing.
Important Facts for Investors to Verify
- Whether the strong wound-care growth and improved gross margin are sustainable after mix, yield, and channel effects.
- Progress, commercialization, required purchases, and contingent profit-share obligations under the TELA/Regenity agreements.
- The regulatory and litigation outcome concerning AXIOFILL and any resulting impact on sales, product classification, or compliance costs.
- Compliance with the Citizens credit agreement’s leverage and fixed-charge-coverage covenants as interest rates and operating conditions change.
- Cash conversion, particularly the effect of rising accounts receivable and inventory on liquidity.
- Potential exposure from pending litigation, indemnification matters, and other contingencies for which no losses were accrued.
- The effect of equity compensation and share issuance on future diluted share count; weighted-average diluted shares were 150.0 million in Q1 2024 versus 114.4 million in Q1 2023.